Brief: Ascletis Pharma - China Nmpa Approved Phase Ii And Iii Protocols Of Asc42, An Fxr Agonist, For Treatment Of Primary Biliary Cholangitis
15/11/2021 01:58
Nov 15 (Reuters) - Ascletis Pharma Inc 1672.HK :
* CHINA NMPA APPROVED PHASE II AND III PROTOCOLS OF ASC42,
AN FXR
AGONIST, FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS
* GANNEX INTENDS TO START A PHASE III TRIAL IN U.S. AND
EUROPEAN
UNION AFTER COMPLETION OF PHASE II STUDY IN CHINA
Source text for Eikon: ID:nHKS3JBwM6
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026